The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
The mutagenic activity of razoxane (ICRF 159) was studied using the Salmonella/microsome assay and rodent bone-marrow micronucleus and metaphase assays. Razoxane (up to 5000 micrograms/plate) did not cause an increase in the mutation frequency in the Salmonella/microsome assay. In the mouse micronucleus assay razoxane (200 and 400 mg kg-1 i.p.) was cytotoxic to the bone marrow cells (which limited the analysis) but an increase in micronucleated polychromatic erythrocytes was observed in razoxane dosed animals (5-fold compared to control value). In the Chinese hamster metaphase assay razoxane (up to 500 mg kg-1 orally) induced abnormal chromosome condensation and an increase in structural chromosome aberrations (7 fold compared to control value) as well as an increase in the number of polypoid cells (8-fold compared to control value). The mutagenic effect of razoxane was restricted to eukaryotic organisms and was associated with specific chromosomal changes.
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D002869:Chromosome Aberrations; D006224:Cricetinae; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects; D008677:Metaphase; D051379:Mice; D008815:Mice, Inbred Strains; D008861:Microsomes; D009152:Mutagenicity Tests / Q000379:methods; D009153:Mutagens; D010879:Piperazines / Q000494:pharmacology*; D011929:Razoxane / Q000494:pharmacology*; D012486:Salmonella typhimurium / Q000187:drug effects
D009153:Mutagens; D010879:Piperazines; D011929:Razoxane